

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cutia Therapeutics

科笛集团

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2487)

VOLUNTARY ANNOUNCEMENT

INVESTIGATIONAL NEW DRUG APPLICATION OF CU-40104 (TOPICAL DUTASTERIDE AGENT) OBTAINED CLINICAL TRIAL APPROVAL BY THE NMPA

This announcement is made by Cutia Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the investigational new drug (IND) application of the Group’s CU-40104 (topical dutasteride agent) has obtained clinical trial approval by the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China. The indication is for the treatment of androgenetic alopecia.

CU-40104 is a self-developed topical dutasteride by the Group. Dutasteride can treat androgenetic alopecia by acting as a competitive and specific inhibitor of both Type I and Type II 5-alpha reductases to inhibit the conversion of testosterone to dihydrotestosterone in the scalp. The Group’s topical formulation under development could deliver dutasteride directly to the site of action on the scalp and is therefore expected to reduce systemic exposure and side effects as compared with oral dutasteride, which is already approved for the treatment of androgenetic alopecia in numerous countries worldwide.

The Group believes that CU-40104 will further expand the Group’s scalp diseases product matrix, and will serve as a valuable complement and synergistic addition to CU-40102 (topical finasteride spray), which has obtained marketing approval by the NMPA.

Warning: There is no assurance that CU-40104 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Cutia Therapeutics
Zhang Lele
Chief Executive Officer and Executive Director

Hong Kong, 16 March 2026

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Mr. Lu Minfang and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Zhang Zhisong and Mr. Ye Xiaoxiang as independent non-executive directors.